Nanosphere Welcomes Ken Bahk, Ph.D. as Chief Strategy Officer and Announces Other Organizational Changes

Nanosphere Welcomes Ken Bahk, Ph.D. as Chief Strategy Officer and Announces 
Other Organizational Changes 
NORTHBROOK, IL -- (Marketwired) -- 04/25/13 --  Nanosphere, Inc.
(NASDAQ: NSPH)  
Appointment of Ken Bahk, Ph.D. 


 
--  Appointed as Chief Strategy Officer to advance Nanosphere's strategic
    plans and help to drive revenues and profitability
--  Highly experienced diagnostic industry professional with deep domain
    expertise and leadership experience at preeminent molecular diagnostic
    organizations
--  Rejoining Nanosphere at a key point in its growth cycle; Dr. Bahk was
    part of the initial Nanosphere team from 2002 to 2008

  
Departures from the Executive Management Team and Board of Directors 


 
--  Tim Patno departing as Chief Technology Officer
--  Chad Mirkin, Ph.D. departing as a Member of the Board of Directors

  
Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and
commercialization of advanced molecular diagnostics systems, today
announced the appointment of Ken Bahk, Ph.D. to the newly created
position of Chief Strategy Officer and the departures of Tim Patno as
Chief Technology Officer and Chad Mirkin, Ph.D. as a Member of the
Board of Directors. 
Reporting to Michael McGarrity, Nanosphere's Chief Executive Officer,
Dr. Bahk will be responsible for advancing the Company's strategic
plans, driving increased and sustainable revenues and retaining a
strong competitive position in the molecular diagnostics space. "I am
particularly pleased to welcome Ken Bahk back to the Nanosphere team.
Ken brings a wide array of skills and expertise and is uniquely
qualified to advance our strategic initiatives. Ken was part of our
initial team at Nanosphere and returns at a key point in our growth
cycle," said Michael McGarrity. "This appointment is consistent with
our focus on commercial execution based on a clear strategy of growth
in key market segments where we can best apply our proprietary
technology and strategic vision."  
Dr. Bahk stated, "I am pleased to be re-joining Nanosphere at this
exciting time, and to have the opportunity to work with Mike's
expanded team to drive value for the company and its shareholders. I
look forward to quickly contributing to advancing our intermediate-and long-term str
ategies by capitalizing on our significant human and
technology capital." 
Regarding the departures from Nanosphere, Michael McGarrity stated,
"On behalf of our Board of Directors, I would like to thank both Tim
Patno and Dr. Mirkin for their significant contributions to
Nanosphere. Tim has helped take our technology from the research
bench at Northwestern to global markets as differentiated and
commercially successful products. Dr. Mirkin helped to co-found
Nanosphere in 2000 and his contributions as a Member of the Board of
Directors since that time have been greatly appreciated. We wish Tim
and Chad well in each of their future endeavors." 
Ken Bahk, Ph.D. 
Ken Bahk, Ph.D. is a Director of Investments at Lurie Investments,
focusing on investments in diagnostics and life sciences. Lurie
Investments, together with its affiliates, is the largest holder of
Nanosphere shares. Dr. Bahk currently serves on the board of
directors of Aperion Biologics, Geneweave Biosciences and Viamet
Pharmaceuticals. Dr. Bahk has been active in leadership positions for
the premier diagnostic and molecular diagnostic organizations, and
most recently was Chair of Strategic Opportunities for the
Association for Molecular Pathology, a committee charged with
understanding key molecular diagnostic and pathology market drivers
and trends. He is a member of the American Association of Clinical
Chemistry, the American Society for Microbiology and the Association
for Molecular Pathology. He received a Ph.D. in biochemistry and
molecular biology and an MS in neurobiology and physiology from
Northwestern University, and an MBA from the Kellogg School of
Management.  
About Nanosphere, Inc.  
Nanosphere develops, manufactures and markets an advanced molecular
diagnostics platform, the Verigene(R) System, for direct genomic and
ultra-sensitive protein detection. This easy to use and cost
effective platform enables simple, low cost and highly sensitive
genomic and protein testing on a single platform. Nanosphere is based
in Northbrook, IL. Additional information is available at
http://www.nanosphere.us. 
Forward Looking Statement - Except for historical information, the
matters discussed in this press release are "forward-looking
statements" and are subject to risks and uncertainties. Actual
results could differ materially from these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, the following: (i)
Nanosphere's ability to develop commercially viable products; (ii)
Nanosphere's ability to achieve profitability; (iii) Nanosphere's
ability to produce and market its products; (iv) Nanosphere's ability
to obtain regulatory approval of its products; (v) Nanosphere's
ability to protect its intellectual property; (vi) competition and
alternative technologies; and (vii) Nanosphere's ability to obtain
additional financing to support its operations. Additional risks are
discussed in the Company's current filings with the Securities and
Exchange Commission. Although the Company believes the expectations
reflected in such forward-looking statements are based on reasonable
assumptions, it can give no assurance that its expectations will be
attained. The forward-looking statements are made as of the date of
this press release, and we undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise. 
Contacts: 
Nanosphere, Inc.
Roger Moody
Chief Financial Officer
847-400-9021
rmoody@nanosphere.us 
or 
LifeSci Advisors
Michael Rice
Founding Partner
646-597-6979
mrice@lifesciadvisors.com 
 
 
Press spacebar to pause and continue. Press esc to stop.